OCULAR THERAPEUTIX, INC (OCUL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67576A1007
OCULAR THERAPEUTIX, INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 51.95 m USD |
| Gross profit | 45.38 m USD |
| Operating income | -270.02 m USD |
| EBIT | -254.10 m USD |
| Net income | -265.94 m USD |
| Diluted EPS – continuing operations | -1.42 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About OCULAR THERAPEUTIX, INC
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
More stocks
- New World Development Co Ltd (17.HK)
- Fujian Snowman Co Ltd (002639.SZ)
- HIAG Immobilien Holding AG (HIAG.SW)
- Trump Media & Technology Group Corp. (DJT)
- Kuaijishan Shaoxing Rice Wine (601579.SS)
- Shinkong Insurance Co Ltd (2850.TW)
- Peptron Inc (087010.KQ)
- Dom Development SA (DOM.WA)
- Changzhou Fusion New Material Co. Ltd. A (688503.SS)
- Northking Information Technology Co (002987.SZ)
- Ryerson Holding Corp (RYZ)
- PharmaBlock Sciences Nanjing Inc Class A (300725.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.